Abstract
Purpose
Immune checkpoint inhibitors (ICIs) are frequently associated with adverse events, often affecting the gastrointestinal tract. We conducted this study to determine the characteristics and outcomes of cancer patients with pre-existing microscopic colitis (MC) who underwent ICI treatment.
Methods
In this retrospective study, we identified 10 patients with pre-existing MC who received ICIs at our center 01/2010–06/2020. Clinical characteristics and disease outcomes were recorded.
Results
Of 124 screened patients with MC before ICI exposure, 10 had sufficient data to be included in the study. Melanoma (40%) and lung cancer (30%) were the most prevalent cancer types, with 70% of stage IV cancer. Patients received either anti-programmed death 1 regimen (8, 80%) or anti-programmed death ligand 1 agent (2, 20%). Six patients (60%) had collagenous colitis, and 4 (40%) had lymphocytic colitis. The median time from MC diagnosis to ICI initiation was 4 years, with 1 patient on budesonide within 2 months of ICI initiation. Eight patients (80%) developed colitis exacerbations after ICI and required selective immunosuppression. One patient received a compassionate-use fecal transplantation. The median time from ICI to colitis exacerbation was 14 days, with 40% and 50% of patients experiencing grade 3 diarrhea and grade 2 colitis, respectively, leading to hospitalization in 3 patients. Six patients received steroids and vedolizumab with no colitis recurrence. Of 8 patients who had colitis exacerbation, 6 resumed ICI therapy afterward; with 5 receiving concomitant vedolizumab for secondary prophylaxis.
Conclusion
Our findings suggest that ICI exposure increases the risk of exacerbation of underlying colitis necessitating and responding to potent immunosuppression therapy.
Similar content being viewed by others
Data availability
The datasets used and analyzed in this study are available from the corresponding author upon reasonable request.
References
Abdel-Wahab N, Shah M, Lopez-Olivo M et al (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med 168(2):121–130
Abu-Sbeih H, Ali F, Naqash A et al (2019) Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 37(30):2738–2745
Abu-Sbeih H, Faleck D, Ricciuti B et al (2020) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 38(6):576–583
Abu-Sbeih H, Zou F, Dutra B et al (2021) Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis. J Clin Oncol 39(15):2642
Ahmed M, Francis G (2018) Pembrolizumab-induced microscopic colitis. Am J Gastroenterol 113(4):629–630
Bohr J, Tysk C, Eriksson S et al (1995) Collagenous colitis in Orebro, Sweden, an epidemiological study 1984–1993. Gut 37(3):394–397
Chaput N, Lepage P, Coutzac C et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368–1379
Choi K, Abu-Sbeih H, Samdani R et al (2019) Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 25(2):385–393
Cindoruk M, Tuncer C, Dursun A et al (2002) Increased colonic intraepithelial lymphocytes in patients with Hashimoto’s thyroiditis. J Clin Gastroenterol 34(3):237–239
Cotter T, Pardi D (2017) Current approach to the evaluation and management of microscopic colitis. Curr Gastroenterol Rep 19(2):8
Grover S, Ruan A, Srivoleti P et al (2020) Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol Pract 16(9):933–942
Günaltay S, Rademacher L, Hörnquist E et al (2017) Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J Gastroenterol 23(7):1319–1324
Hillock N, Heard S, Kichenadasse G et al (2017) Infliximab for ipilimumab-induced colitis: a series of 13 patients. Asia Pac J Clin Oncol 13(5):284–290
Holster S, Rode J, Bohr J et al (2020) Faecal microbiota transfer in patients with microscopic colitis - a pilot study in collagenous colitis. Scand J Gastroenterol 55(12):1454–1466
Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193–3198
Ianiro G, Cammarota G, Valerio L et al (2012) Microscopic colitis. World J Gastroenterol 18(43):6206–6215
Jegadeesan R, Liu X, Pagadala M et al (2013) Microscopic colitis: is it a spectrum of inflammatory bowel disease? World J Gastroenterol 19(26):4252–4256
Johnson D, Sullivan R, Ott P et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234–240
Matteoni C, Goldblum J, Wang N et al (2001) Celiac disease is highly prevalent in lymphocytic colitis. J Clin Gastroenterol 32(3):225–227
Menzies A, Johnson D, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368–376
Michot J, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148
Nielsen D, Juhl C, Chen I, et al. Immune checkpoint inhibitor-induced diarrhea and colitis: dncidence and management. A systematic review and meta-analysis. Cancer Treat Rev. 2022;109:102440.
Pardi D (2017) Diagnosis and management of microscopic colitis. Am J Gastroenterol 112(1):78–85
Park T, Cave D, Marshall C (2015a) Microscopic colitis: a review of etiology, treatment and refractory disease. World J Gastroenterol 21(29):8804–8810
Park EK, Park YS, Park DR et al (2015b) Cytokine expression of microscopic colitis including interleukin-17. Gut Liver 9(3):381–387
Robert C, Schachter J, Long G (2015) Pembrolizumab versus ipilimumab in advanced melanoma. NEJM 372:2521–2532
Sharma P, Siddiqui B, Anandhan S et al (2021) The next decade of immune checkpoint therapy. Cancer Discov 11(4):838–857
Storr M (2013) Microscopic colitis: epidemiology, pathophysiology, diagnosis and current management-an update 2013. ISRN Gastroenterol 2013:352718
Tagkalidis P, Gibson P, Bhathal P (2007) Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J Clin Pathol 60(4):382–387
Tang L, Wang J, Lin N et al (2021) Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol 12:800879
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf [accessed on 4 March 2022].
Wang Y, Wiesnoski D, Helmink B et al (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804–1808
Wickbom A, Bohr J, Nyhlin N et al (2018) Microscopic colitis in patients with ulcerative colitis or Crohn’s disease: a retrospective observational study and review of the literature. Scand J Gastroenterol 53(4):410–416
Wynat T, Fedyk E, Abhyanker B (2016) An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis 10(12):1437–1444
Yeung S, Odaisat A, Chaftari P et al (2020) Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J Am Coll Emerg Physicians Open 1(6):1637–1659
Zou F, Abu-Sbeih H, Ma W et al (2020) Association of chronic immune-mediated diarrhea and colitis with favorable cancer response. J Natl Compr Canc Netw 19(6):700–708
Zou F, Faleck D, Thomas A et al (2021) Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 9(11):e003277
Acknowledgements
Medical editing of this paper was provided by Laura L. Russell in the Research Medical Library at The University of Texas MD Anderson Cancer Center.
Funding
This study was not supported by any funding.
Author information
Authors and Affiliations
Contributions
YW and AT were the senior authors of the study, developed the concept, designed the study, interpreted the results, ensured the preservation of data accuracy and integrity at all stages, agreed to be accountable for all aspects of the study, were in charge of the overall direction and planning of the study, and contributed to the writing of the manuscript with input from all authors. AT and CL collected the data for the study, conducted the analysis, interpreted the results, and wrote the manuscript. YT and DT collected the pathology images. MA, BAS, MS, and AK critically revised the final version of the manuscript. All authors had access to the study data and reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Conflict of interest
None of the authors have competing interests.
Ethics approval and consent to participate
Ethics approval for this study was granted by the Institutional Review Board of the University of Texas MD Anderson Cancer Center (PA18-0472). Patient consent was waived for this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Thomas, A.R., Liu, C., Tong, Y.T. et al. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. J Cancer Res Clin Oncol 149, 5429–5436 (2023). https://doi.org/10.1007/s00432-022-04499-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04499-9